Search results (1320)
« Back to PublicationsRole of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic.
Skolariki A. et al, (2022), Explor Target Antitumor Ther, 3, 172 - 199
Ezh2 is essential for the generation of functional yolk sac derived erythro-myeloid progenitors.
Neo WH. et al, (2021), Nat Commun, 12
The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial.
Schwenzer H. et al, (2021), Clin Cancer Res, 27, 6500 - 6513
A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program.
Rice S. et al, (2021), Nat Commun, 12
A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis
Gill H. et al, (2021), BLOOD, 138
Single-Cell Multi-Omics Reveals the Genetic, Cellular and Molecular Landscape of TP53 Mutated Leukemic Transformation in MPN
Rodriguez-Meira A. et al, (2021), BLOOD, 138
Burden of cancer trial participation: A qualitative sub-study of the INTERIM feasibility RCT.
Nwolise C. et al, (2021), Chronic Illn
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.
Collins GP. et al, (2021), Leuk Lymphoma, 62, 2625 - 2636
A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma.
Collins GP. et al, (2021), Hemasphere, 5
Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
Weber JS. et al, (2021), Eur J Cancer, 158, 225 - 233
The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders.
Cross NCP. et al, (2021), Br J Haematol, 195, 338 - 351
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
Wang M. et al, (2021), J Hematol Oncol, 14
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer
Kazmi F. et al, (2021), Cochrane Database of Systematic Reviews, 2021
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.
Fox CP. et al, (2021), Blood Adv, 5, 4073 - 4082
Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation.
Campbell NR. et al, (2021), Dev Cell, 56, 2808 - 2825.e10
Message in a platelet: decoding platelet transcriptomes in myeloproliferative neoplasms.
Shapiro S. et al, (2021), Cell Rep Med, 2
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).
Pagano L. et al, (2021), J Hematol Oncol, 14
CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) PROTEIN INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK INHIBITOR-NAIVE MYELOFIBROSIS PATIENTS: UPDATE OF MANIFEST PHASE 2 STUDY
Palandri F. et al, (2021), HAEMATOLOGICA, 106, 5 - 6
Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8+ T cell clone size and cytotoxicity.
Watson RA. et al, (2021), Sci Immunol, 6
Interferon-Gamma-Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Colitis.
Sasson SC. et al, (2021), Gastroenterology, 161, 1229 - 1244.e9